Ovamex (Ganirelix)

Ganirelix, the active ingredient in Ovamex, is a GnRH antagonist presented as an injectable solution for subcutaneous use. It is employed to prevent premature luteinising hormone surges during assisted reproductive treatment cycles. GNH USA supplies Ovamex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ganirelix is used in assisted reproductive technology to modulate the hormonal pathway that controls ovulation. - Controlled ovarian stimulation: prevents premature LH surge during IVF cycles, allowing better timing of oocyte retrieval. - Assisted reproductive technology: improves synchronization of follicular development for embryo transfer. - In vitro fertilisation protocols: enhances control over the ovarian response to gonadotropins.

Ganirelix may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: mild discomfort at the site of subcutaneous administration. - Headache: occasional tension‑type headache. - Nausea: transient feeling of queasiness. - Abdominal discomfort: mild cramping or bloating. - Hot flushes: brief episodes of warmth. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: severe swelling and fluid shift in response to ovarian stimulation. - Allergic reaction: rash, itching, or anaphylaxis in rare cases. - Severe abdominal pain: may indicate ovarian torsion or cyst rupture. - Thromboembolic events: rare clot formation. - Ovarian cyst formation: persistent cysts requiring monitoring. - Severe hypersensitivity: swelling of face, lips, or throat.

When using Ganirelix, consider the following safety measures. - Pregnancy: avoid use in women who are already pregnant; the drug is intended for pre‑ovulatory control. - Breastfeeding: exercise caution as limited data are available on excretion in milk. - Allergy assessment: verify no hypersensitivity to ganirelix or formulation excipients. - Hormonal monitoring: regularly assess LH and estradiol levels during treatment. - Concomitant hormonal therapy: review other reproductive hormones for potential interactions. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Ganirelix can interact with other agents that affect the reproductive hormonal axis.

Major Interactions (Avoid): - GnRH agonists: concurrent use may counteract the antagonist effect. - Hormonal contraceptives: may reduce contraceptive efficacy. - Ovarian stimulation drugs: overlapping mechanisms can increase risk of hyperstimulation.

Moderate Interactions (Monitor Closely): - CYP450 modulators: may alter ganirelix metabolism; monitor response. - Anticoagulants: monitor for bleeding if ovarian hyperstimulation occurs. - Diuretics: watch for electrolyte shifts during fluid changes in hyperstimulation.